Life Biosciences said it has treated the first participant in a gene therapy trial designed for partial cellular reprogramming, reported in the provided content. The approach turns on three genes intended to shift aged cells toward a younger state while aiming to avoid full loss of cell identity. The initial indication is glaucoma, with the goal of enabling regeneration of optic nerve neurons that typically do not regenerate in adults. The trial’s stated focus is safety given long-standing concerns that partial reprogramming could raise tumor risk. Launching in the eye may reduce systemic risk exposure compared with approaches targeting more vulnerable organs, but regulators and investigators will still scrutinize on-target effects and any evidence of uncontrolled growth potential.